ADPT (Adaptive Biotechnologies) LT-Debt-to-Total-Asset: 0.14 (As of Mar. 2026)

What is Adaptive Biotechnologies LT-Debt-to-Total-Asset?

Adaptive Biotechnologies ADPT +0.23% 67 LT-Debt-to-Total-Asset is 0.14 as of Mar. 2026. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.06 (Significantly Overvalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Adaptive Biotechnologies's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.14.

Adaptive Biotechnologies's long-term debt to total assets ratio declined from Mar. 2025 (0.15) to Mar. 2026 (0.14). It may suggest that Adaptive Biotechnologies is progressively becoming less dependent on debt to grow their business.

Adaptive Biotechnologies (NAS:ADPT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Adaptive Biotechnologies LT-Debt-to-Total-Asset Related Terms

Adaptive Biotechnologies LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies LT-Debt-to-Total-Asset Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.12

0.14

0.15

0.14

Adaptive Biotechnologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.15	0.15	0.15	0.14	0.14

67GF Score

Adaptive Biotechnologies Corp ADPT

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Adaptive Biotechnologies LT-Debt-to-Total-Asset Calculation

Adaptive Biotechnologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	70.228	/	512.736
	=	0.14

Adaptive Biotechnologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	69.115	/	505.943
	=	0.14

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.14 mean?

Adaptive Biotechnologies (ADPT) has a LT-Debt-to-Total-Asset of 0.14 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Adaptive Biotechnologies and its competitors.

Is Adaptive Biotechnologies' LT-Debt-to-Total-Asset too high?

Adaptive Biotechnologies' current LT-Debt-to-Total-Asset is 0.14. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Adaptive Biotechnologies' LT-Debt-to-Total-Asset compare to GRAL and WGS?

Adaptive Biotechnologies' LT-Debt-to-Total-Asset of 0.14 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?

A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current LT-Debt-to-Total-Asset is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Adaptive Biotechnologies stock overvalued right now?

Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $21.45 — trading 113.2% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.14. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current LT-Debt-to-Total-Asset is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $21.45 is trading 113.2% above its estimated GF Value™ of $10.06. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

LT-Debt-to-Total-Asset: 0.14
GF Value™: $10.06 vs. price of $21.45 (113.2% above fair value)
GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies GRAL WGS RDNT VCYT NEO SHC CDNA PSNL BLLN OPK TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN

Other Exchanges 1HM:Germany

Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

67GF Score

Get the complete analysis for ADPT

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.45

Price

$10.06

GF Value

View ADPT Analysis

See LT-Debt-to-Total-Asset data for all stocks →